Ausgabe 5/2016
Inhalt (9 Artikel)
Neuroscience-based nomenclature (jNbN) to replace traditional terminology of psychotropic medications
Hans-Jürgen Möller, Andrea Schmitt, Peter Falkai
Negative symptoms and their association with depressive symptoms in the long-term course of schizophrenia
Wolfram an der Heiden, Anne Leber, Heinz Häfner
Neurocognitive impairment in the deficit subtype of schizophrenia
Gagan Fervaha, Ofer Agid, George Foussias, Ishraq Siddiqui, Hiroyoshi Takeuchi, Gary Remington
Attentional dysfunction in abstinent long-term cannabis users with and without schizophrenia
Johannes Rentzsch, Ada Stadtmann, Christiane Montag, Hagen Kunte, Doris Plöckl, Rainer Hellweg, Jürgen Gallinat, Golo Kronenberg, Maria Christiane Jockers-Scherübl
Smaller than expected cognitive deficits in schizophrenia patients from the population-representative ABC catchment cohort
Leonhard Lennertz, Wolfram an der Heiden, Regina Kronacher, Svenja Schulze-Rauschenbach, Wolfgang Maier, Heinz Häfner, Michael Wagner
The role of Pannexin gene variants in schizophrenia: systematic analysis of phenotypes
Micha Gawlik, Martin Wagner, Bruno Pfuhlmann, Gerald Stöber
Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials
Kazuto Oya, Yuki Matsuda, Shinji Matsunaga, Taro Kishi, Nakao Iwata
First- and second-generation antipsychotic drug treatment and subcortical brain morphology in schizophrenia
Kjetil N. Jørgensen, Ragnar Nesvåg, Sindre Gunleiksrud, Andrea Raballo, Erik G. Jönsson, Ingrid Agartz
Endurance training in patients with schizophrenia and healthy controls: differences and similarities
Katriona Keller-Varady, Alkomiet Hasan, Thomas Schneider-Axmann, Ursula Hillmer-Vogel, Björn Adomßent, Thomas Wobrock, Andrea Schmitt, Andree Niklas, Peter Falkai, Berend Malchow